About this trial
In the last years, the imbalance between excitatory and inhibitory neuronal activity has come to the fore as a possible molecular disease mechanism of schizophrenia . Pharmacological studies have suggested different fMRI and EEG markers of that molecular dysfunction (resting state connectivity changes, auditory mismatch and steady state deficits). However, previous research is inconclusive regarding their genetic basis, their reliability, inter-individual relationship as well as disease specificity. Therefore, in this study we aim at estimating the effect sizes, test-retest-reliability and clinical correlates of the respective markers in a comparative fashion in patients with schizophrenia, their relatives and healthy control subject. To assess their molecular validity, we will assess their relationship with glutamatergic and GABAergic genotypes and cellular disease models. The proof of such a relation would give the opportunity of detecting a glutamatergic and GABAergic imbalance throughout non-invasive imaging. Furthermore, it would help deepening our understanding of the molecular pathophysiology of mental disorders which will be essential for the development of more effective drugs.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
diagnosis of schizophrenia according to DSM-5
aged 18 to 80
being mentally and contractually capable to give their consent to study participation
Disqualifiers
pregnancy
structural neurological disease
a further psychiatric comorbidity that dominates in the clinical appearance
aged 18 to 80
Trial population
The patients will be recruited from the Department of Psychiatry, Psychotherapy and Psychosomatics at Uniklinik RWTH Aachen, Alexianer Krankenhaus and the psychiatric institutions of Katharina Kasper ViaNobis GmbH in Gangelt. The patients will be asked whether their healthy relatives may be contacted in terms of study participation. Additionally, they will be handed the study teams' contact details. Relatives suffering from the same psychiatric disorder as the patients can also be included and will be contacted the same way as the healthy relatives. Healthy controls will be searched via notices in the Uniklinik RWTH Aachen. Furthermore, we will contact former study participants that have given their consent to being contacted for a renewed study participation.
Trial design
Case-control
Prospective
Treatments tested in this trial
Genotyping
GeneticGenotyping of glutamatergic, GABAergic, dopaminergic and other CNS-related genes
Treatment groups
Trial outcomes
Primary outcomes
MMN
Mismatch negativity amplitude
ASSR Power
40-Hz auditory steady state response spectral power
Secondary outcomes
ASSR Phase Locking
40-Hz auditory steady state response phase locking
Functional connectivity
Whole brain resting state functional connectivity matrix
Psychopathology as assessed with the PANSS
Positive and negative syndrome scale (Minimum: 30, Maximum: 210, higher scores mean worse outcome)
Psychopathology as assessed with the BPP
Berner Psychopathologie-Skala (Minimum: -3, Maximum: +3, higher positive scores mean excessive speech, movements or higher positive affect, higher negative scores mean a lack of speech, movements or higher negative affect,
Sponsors and contacts
Click on the lead sponsor to view all of their trials.